Literature DB >> 9439826

Intra-amygdala infusion of 2-chloroadenosine suppresses amygdala-kindled seizures.

M H Pourgholami1, M Rostampour, J Mirnajafi-Zadeh, M R Palizvan.   

Abstract

The seizure-modulating effects of 2-chloroadenosine (2-CLA) infused directly into the amygdala were investigated. Different groups of amygdala-kindled rats were infused (1 microliter) with 2-CLA (0.25, 1, 10 and 25 nM), caffeine (200 microM and 2 mM), a combination of the two or artificial cerebrospinal fluid (ACSF) applied directly through a cannula located in the amygdala. Infusion of 2-CLA dramatically suppressed seizure stage (SS), after discharge duration (ADD) and stage 5 seizure duration (S5D), while the latency to bilateral forelimb clonus (S4L) was significantly prolonged. These anticonvulsant effects were evident after 5 min, reached a maximum at the 60 min time point and were still detectable 360 min post-2-CLA infusion. Pretreatment with caffeine blocked the anticonvulsant effects of 2-CLA dose-dependently. These results may suggest that in amygdaloid-kindled rats, adenosine receptors located in the amygdala play a major role in the expression of the anticonvulsant activity of 2-CLA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9439826     DOI: 10.1016/s0006-8993(97)00769-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  4 in total

1.  Purines and the Anti-Epileptic Actions of Ketogenic Diets.

Authors:  Susan A Masino; Masahito Kawamura; David N Ruskin; Jeremy Gawryluk; Xuesong Chen; Jonathan D Geiger
Journal:  Open Neurosci J       Date:  2010-01-01

2.  A1 adenosine receptors inhibit multiple voltage-gated Ca2+ channel subtypes in acutely isolated rat basolateral amygdala neurons.

Authors:  B A McCool; J S Farroni
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

Review 3.  Intraventricular and intracerebral delivery of anti-epileptic drugs in the kindling model.

Authors:  Juan A Barcia; José M Gallego
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

Review 4.  Bypassing the Blood-Brain Barrier: Direct Intracranial Drug Delivery in Epilepsies.

Authors:  Manuela Gernert; Malte Feja
Journal:  Pharmaceutics       Date:  2020-11-24       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.